Erika Hamilton

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, G. Borges et autres

us, br, il, it, es, be, de (code pays fourni par la source)

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Hope S. Rugo, K. Jhaveri, Sònia Pernas, Barbara Pistilli et autres

us, es, fr, kr, it, cn, ca, jp, tw, br, pl, sg (code pays fourni par la source)

The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer Treatment

Sara M. Tolaney, Sibylle Loibi, Mothaffar F. Rimawi, Erika Hamilton et autres

us, de, kr (code pays fourni par la source)

Abstract 3149: Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043

Colette L Baxter, Timothy A. Yap, Susanna V. Ulahannan, Nehal J. Lakhani et autres

gb, us (code pays fourni par la source)

Supplementary Data 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Table 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Figure 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Figure 2 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Supplementary Data 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Table 2 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Figure 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

Supplementary Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Christopher T. Chen, Vishesh Khanna, Shivaani Kummar, Raghad M. Abdul-Karim et autres